Journal
ARTHRITIS RESEARCH & THERAPY
Volume 6, Issue 6, Pages 240-247Publisher
BMC
DOI: 10.1186/ar1444
Keywords
bone; cytokines; interleukin-17; inflammation; synergy
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329] Funding Source: NIH RePORTER
- NIAID NIH HHS [AI49329, R21 AI049329, R01 AI049329] Funding Source: Medline
Ask authors/readers for more resources
IL-17 and its receptor are founding members of an emerging family of cytokines and receptors with many unique characteristics. IL-17 is produced primarily by T cells, particularly those of the memory compartment. In contrast, IL-17 receptor is ubiquitously expressed, making nearly all cells potential targets of IL-17. Although it has only limited homology to other cytokines, IL-17 exhibits proinflammatory properties similar to those of tumor necrosis factor-alpha, particularly with respect to induction of other inflammatory effectors. In addition, IL-17 synergizes potently with other cytokines, placing it in the center of the inflammatory network. Strikingly, IL-17 has been associated with several bone pathologies, most notably rheumatoid arthritis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available